Disparities in adherence to retesting guidelines in women with Trichomonas vaginalis infection.
Trichomonas vaginalis and pregnancy
healthcare disparities
infectious disease and pregnancy
prevalence rate Trichomonas vaginalis
sexually transmitted disease and prevalence
sexually transmitted diseases and pregnancy
Journal
American journal of obstetrics and gynecology
ISSN: 1097-6868
Titre abrégé: Am J Obstet Gynecol
Pays: United States
ID NLM: 0370476
Informations de publication
Date de publication:
09 2023
09 2023
Historique:
received:
12
01
2023
revised:
08
05
2023
accepted:
21
06
2023
pmc-release:
01
09
2024
medline:
28
8
2023
pubmed:
2
7
2023
entrez:
1
7
2023
Statut:
ppublish
Résumé
Trichomoniasis is the most prevalent nonviral sexually transmitted infection in the United States. Numerous studies have shown disproportionately higher prevalence rates in non-Hispanic Black women. Because of the high rates of reinfection, the Centers for Disease Control and Prevention recommends retesting women treated for trichomoniasis. Despite these national guidelines, there are few studies examining adherence to retesting recommendations for patients with trichomoniasis. Adherence to retesting guidelines has been shown in other infections to be an important determinant of racial disparities. This study aimed to describe Trichomonas vaginalis infection rates, evaluate adherence to retesting guidelines, and examine characteristics of women who were not retested according to the guidelines in an urban, diverse, hospital-based obstetrics and gynecology clinic population. We conducted a retrospective cohort study of patients from a single hospital-based obstetrics and gynecology clinic who were tested for Trichomonas vaginalis between January 1, 2015 and December 31, 2019. Descriptive statistics were used to examine guideline-concordant testing for reinfection among patients with trichomoniasis. Multivariable logistic regression was used to identify characteristics associated with testing positive and with appropriate retesting. Subgroup analyses were performed for patients who were pregnant and tested positive for Trichomonas vaginalis. Among the 8809 patients tested for Trichomonas vaginalis, 799 (9.1%) tested positive at least once during the study. Factors associated with trichomoniasis included identifying as non-Hispanic Black (adjusted odds ratio, 3.13; 95% confidence interval, 2.52-3.89), current or former tobacco smoking (adjusted odds ratio, 2.27; 95% confidence interval, 1.94-2.65), and single marital status (adjusted odds ratio, 1.96; 95% confidence interval, 1.51-2.56). Similar associated factors were found in the pregnant subgroup analysis. For women with trichomoniasis, guideline-concordant retesting rates were low across the entire population, with only 27% (214/799) of patients retested within the recommended time frame; 42% (82/194) of the pregnant subgroup underwent guideline-concordant retesting. Non-Hispanic Black women had significantly lower odds of undergoing guideline-recommended retesting than non-Hispanic White women (adjusted odds ratio, 0.54; 95% confidence interval, 0.31-0.92). Among patients tested according to guideline recommendations, we found a high rate of Trichomonas vaginalis positivity at retesting: 24% in the entire cohort (51/214) and 33% in the pregnant subgroup (27/82). Trichomonas vaginalis infection was identified at a high frequency in a diverse, urban hospital-based obstetrics and gynecology clinic population. Opportunities exist to improve on equitable and guideline-concordant retesting of patients with trichomoniasis.
Sections du résumé
BACKGROUND
Trichomoniasis is the most prevalent nonviral sexually transmitted infection in the United States. Numerous studies have shown disproportionately higher prevalence rates in non-Hispanic Black women. Because of the high rates of reinfection, the Centers for Disease Control and Prevention recommends retesting women treated for trichomoniasis. Despite these national guidelines, there are few studies examining adherence to retesting recommendations for patients with trichomoniasis. Adherence to retesting guidelines has been shown in other infections to be an important determinant of racial disparities.
OBJECTIVE
This study aimed to describe Trichomonas vaginalis infection rates, evaluate adherence to retesting guidelines, and examine characteristics of women who were not retested according to the guidelines in an urban, diverse, hospital-based obstetrics and gynecology clinic population.
STUDY DESIGN
We conducted a retrospective cohort study of patients from a single hospital-based obstetrics and gynecology clinic who were tested for Trichomonas vaginalis between January 1, 2015 and December 31, 2019. Descriptive statistics were used to examine guideline-concordant testing for reinfection among patients with trichomoniasis. Multivariable logistic regression was used to identify characteristics associated with testing positive and with appropriate retesting. Subgroup analyses were performed for patients who were pregnant and tested positive for Trichomonas vaginalis.
RESULTS
Among the 8809 patients tested for Trichomonas vaginalis, 799 (9.1%) tested positive at least once during the study. Factors associated with trichomoniasis included identifying as non-Hispanic Black (adjusted odds ratio, 3.13; 95% confidence interval, 2.52-3.89), current or former tobacco smoking (adjusted odds ratio, 2.27; 95% confidence interval, 1.94-2.65), and single marital status (adjusted odds ratio, 1.96; 95% confidence interval, 1.51-2.56). Similar associated factors were found in the pregnant subgroup analysis. For women with trichomoniasis, guideline-concordant retesting rates were low across the entire population, with only 27% (214/799) of patients retested within the recommended time frame; 42% (82/194) of the pregnant subgroup underwent guideline-concordant retesting. Non-Hispanic Black women had significantly lower odds of undergoing guideline-recommended retesting than non-Hispanic White women (adjusted odds ratio, 0.54; 95% confidence interval, 0.31-0.92). Among patients tested according to guideline recommendations, we found a high rate of Trichomonas vaginalis positivity at retesting: 24% in the entire cohort (51/214) and 33% in the pregnant subgroup (27/82).
CONCLUSION
Trichomonas vaginalis infection was identified at a high frequency in a diverse, urban hospital-based obstetrics and gynecology clinic population. Opportunities exist to improve on equitable and guideline-concordant retesting of patients with trichomoniasis.
Identifiants
pubmed: 37393012
pii: S0002-9378(23)00443-X
doi: 10.1016/j.ajog.2023.06.045
pmc: PMC10530237
mid: NIHMS1922998
pii:
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
284.e1-284.e10Subventions
Organisme : NCI NIH HHS
ID : K07 CA230234
Pays : United States
Organisme : NIAID NIH HHS
ID : K23 AI159518
Pays : United States
Informations de copyright
Copyright © 2023 Elsevier Inc. All rights reserved.
Références
Clin Infect Dis. 2007 Nov 15;45(10):1319-26
pubmed: 17968828
Sex Transm Dis. 2005 Oct;32(10):593-8
pubmed: 16205299
Int J STD AIDS. 2017 Oct;28(11):1130-1134
pubmed: 28134005
Emerg Infect Dis. 2012 Jun;18(6):939-43
pubmed: 22608054
J Low Genit Tract Dis. 2012 Oct;16(4):352-7
pubmed: 22968052
Curr Infect Dis Rep. 2015 Jun;17(6):484
pubmed: 25925796
Sex Transm Dis. 2017 Nov;44(11):695-699
pubmed: 28876306
Sex Transm Infect. 2013 Sep;89(6):426-33
pubmed: 23605851
Sex Transm Dis. 2018 May;45(5):e23-e24
pubmed: 29465684
Am J Obstet Gynecol. 2018 Mar;218(3):328.e1-328.e13
pubmed: 29247635
J Clin Microbiol. 2012 Aug;50(8):2601-8
pubmed: 22622447
Clin Infect Dis. 2018 Jul 2;67(2):211-217
pubmed: 29554238
Sex Transm Dis. 2014 Jun;41(6):369-76
pubmed: 24825333
Clin Infect Dis. 2015 Dec 15;61 Suppl 8:S837-48
pubmed: 26602621
BMC Infect Dis. 2015 Aug 05;15:307
pubmed: 26242185
PLoS One. 2014 Mar 13;9(3):e90548
pubmed: 24626058
PLoS One. 2017 Mar 27;12(3):e0173604
pubmed: 28346531
Sex Transm Dis. 1997 Jul;24(6):353-60
pubmed: 9243743
Sex Transm Dis. 2013 Feb;40(2):113-6
pubmed: 23321992
F1000Res. 2019 Sep 20;8:
pubmed: 31583080
Sex Transm Infect. 2013 Sep;89(6):418-22
pubmed: 23744960
Sex Transm Dis. 2014 Apr;41(4):240-5
pubmed: 24622635
Sex Transm Dis. 2019 Oct;46(10):e93-e96
pubmed: 31517807
Emerg Infect Dis. 2001 Nov-Dec;7(6):927-32
pubmed: 11747718
Sex Transm Dis. 2004 Sep;31(9):547-51
pubmed: 15480116
Clin Infect Dis. 2008 Apr 1;46(7):994-9
pubmed: 18444815
Sex Transm Dis. 2013 Mar;40(3):187-93
pubmed: 23403598